Business Wire

eG Innovations Joins the Nutanix Elevate Technology Alliance Partner Program, Delivering End-to-End Performance Monitoring

Del

Today at VMworld® 2016 Europe, eG Innovations, a leading IT performance management software provider, announced that it has joined the Nutanix Elevate Technology Alliance Partner Program and completed the Nutanix Ready validation for AHV, Hyper-V, and vSphere running on Nutanix.

eG Innovations delivers performance-monitoring solutions for Nutanix cloud-based environments, helping enterprises and service providers monitor their network, server, virtualization, storage and application tiers from a single pane of glass. eG Enterprise offers broad coverage including support for 180+ common applications, 10+ virtualization platforms and 10+ operating systems.

The Nutanix enterprise cloud platform is being used by thousands of customers to run business critical applications and servers. If and when performance issues arise, IT teams often struggle to determine where the problem lies: is it in the network, or the server or the virtualization tier, or storage, or due to the applications? This is where eG Innovations’ technology comes in.

eG Enterprise, the flagship product from eG Innovations, provides Nutanix customers total performance visibility throughout the Nutanix enterprise cloud infrastructure covering key components such as hypervisors, virtual machines, storage disks, clusters, and containers. eG Enterprise’s inside-outside monitoring technology for virtual infrastructures now supports Nutanix AHV as well. Furthermore, its patented virtualization-aware root-cause diagnosis technology auto-discovers application-to-virtual machine and virtual machine-to-physical machine relationships in Nutanix environments, and uses this dependency information for automated root-cause diagnosis.

“Performance monitoring today is not about just tracking server and network resources. IT teams are measured by user satisfaction and productivity. eG Innovations’ technologies help IT teams achieve these goals by enabling them to monitor the real user experience, pinpoint where performance bottlenecks are and resolve them quickly to ensure user satisfaction and productivity,” said Srinivas Ramanathan, chief executive officer, eG Innovations. “We are excited to be a member of Elevate as an alliance partner of Nutanix. Together we are enhancing our technologies to ensure lower total cost of ownership and increased return on investment for our customers.”

The Nutanix Elevate Technology Alliance Program provides partners with technical resources, testing and documentation processes, marketing support, and sales enablement to develop comprehensive customer solutions. Nutanix Elevate Partners deliver validated solutions to market in the areas of Application Development, Applications and Operating Systems, Backup and Disaster Recovery, Desktop and Application Virtualization, Hybrid Cloud, Management and Operations, and Networking and Security.

To learn more, visit the eG Innovations website. For an exclusive preview, visit eG Innovations on-site at VMWorld Europe Booth #624.

About eG Innovations
eG Innovations is dedicated to helping businesses across the globe transform IT service delivery into a competitive advantage and a center for productivity, growth and profit. Many of the world's largest businesses use eG Enterprise Universal Insight and Correlative Intelligence technologies to enhance IT service performance, increase operational efficiency, ensure IT effectiveness and deliver on the ROI promise of transformational IT investments across physical, virtual and cloud environments.

All trademarks, service marks and company names are the property of their respective owners.

Contact information

eG Innovations
Erin Farrell Talbot, 917-232-9309
erin@farrelltalbot.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00Pressemelding

Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33Pressemelding

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

CTS Engines Announces Senior Management Hire12.12.2017 13:00Pressemelding

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00Pressemelding

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s

LTI to Offer Blockchain Solution Powered by Microsoft Azure12.12.2017 10:45Pressemelding

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, announced today the availability of its blockchain-based trade finance solution on Microsoft Azure marketplace. The solution tracks the flow of goods in a value chain, improving transparency across multiple entities involved. It enables accelerated adoption of distributed ledger technologies by bringing together LTI’s deep industry knowledge and blockchain capabilities together with Microsoft’s expertise in cloud-based solutions. Aftab Ullah, Chief Operating Officer, LTI said, "Our vision is to deliver exponential operational efficiencies to the world’s leading companies through digital innovation. LTI’s Blockchain services include end-to-end consulting and implementation and are designed to help transform our clients’ business operations. The collaboration

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom